Which CLL drug gives best bang for the buck? new study analyzes costs and patient Well-Being
NCT ID NCT02414022
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. The goal is to help public health systems decide which treatment offers the best value.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib, rituximab, bendamustine
What this could lead to
If successful, this could help healthcare systems decide which treatment offers the best value for money in older CLL patients.
What could go wrong
This is an economic analysis of a small subset of patients, not a new treatment trial. Results may not apply to all patients or healthcare settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
-
CHUM-CEntre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
-
CSSS Champlain-Charles LeMoyne
Greenfield Park, Quebec, Canada
-
Health Sciences North
Greater Sudbury, Ontario, Canada
-
Humber River Hospital
Toronto, Ontario, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L3N6, Canada
-
London Regional Cancer Program
London, Ontario, Canada
-
Odette Cancer Centre Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
-
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, L3Y 2P9, Canada
-
The Jewish General Hospital
Montreal, Quebec, Canada
-
The Moncton Hospital
Moncton, New Brunswick, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, Canada
-
University Health Network Princess Margaret Cancer Centre
Toronto, Ontario, Canada